Galcanezumab for the prophylaxis of episodic and chronic migraine

featured image
Indications: Migraine
Therapeutic Areas: Neurology
Year: 2017

Galcanezumab is being developed as one of a class of specific anti-migraine preventative drugs. By stopping a very specific protein in the brain and nervous system, galcanezumab reduces migraine attacks. Additionally as it is given once-a-month as treatment, it avoids the need to take numerous pills per day. If marketed, galcanezumab may be more preferable to current treatment options for episodic migraine and chronic migraine prevention.